A Minnesota cardiology firm that develops transcatheter septal occluders to repair congenital heart defects in children and adults has raised $2.08 million, according to a regulatory filing.
Cardia’s septal occluders, new innovative medical devices that are cardiac implants, repair a cardiac defect known as a “hole in the heart.”
It appears that Cardia is the name of a company with a product line that originally came out of Germany. Cardia’s chief executive officer since inception in 1998 is Joseph Marino, whose previous tenure was at Applied Biometrics, which bought a transcatheter closure product line from Schneidt Implantate in an equity transaction. Later Applied Biometrics was liquidated.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cardia appears to be an asset that survived. Cardia’s products are not approved in the U.S., but are available in some overseas markets including Europe. In 2002, the company raised $345,000.
